Instituto Nacional de Cardiología Ignacio Chávez
Mexico City, 14080, Mexico
NCT Number: NCT06584734
Introduction: Cardiovascular disease is the leading cause of morbidity and mortality in patients undergoing hemodialysis, largely due to structural cardiac changes associated with left ventricular diastolic dysfunction. In addition, this population has a high prevalence of sedentary behavior, which has been associated with increased mortality. Recent studies in patients with chronic kidney disease have shown that structured exercise interventions improve several parameters related to cardiovascular health.
Objectives: To evaluate the effect of implementing systematic intradialytic exercise on left ventricular diastolic function.
Materials and Methods: This will be a quasi-experimental before-and-after study conducted in two phases. During the first phase (control), prevalent hemodialysis patients will receive standard treatment for 16 weeks. Transthoracic echocardiography will be performed at baseline and repeated at the end of this phase to assess left ventricular diastolic function parameters. During the second phase (intradialytic exercise), participants will undergo a 16-week supervised and prescribed intradialytic aerobic exercise program consisting of intradialytic cycling. Exercise intensity will be individualized according to cardiopulmonary exercise testing (CPET), which will be performed at the beginning and end of this phase. A final echocardiogram will be obtained at the end of the intervention phase. In addition, a 6-minute walk test and a validated physical activity questionnaire will be administered monthly throughout both phases of the study.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Mexico City, 14080, Mexico
Left Ventricular Diastolic Function worsens during the hemodialysis session mainly due to preload effects. However, studies in patients with advanced CKD (pre-dialysis) have shown benefits in diastolic function when subjected to exercise programs. Based on this, implementing a standardized and protocolized exercise regimen during the hemodialysis session could provide cardiovascular benefits, specifically in terms of improving left ventricular diastolic function in this population.
The implementation of intradialytic exercise in the hemodialysis unit of our Institute began in 1994. However, there is no standardized or systematic process for intradialytic exercise.
This leads us to ask the following question: What is the effect of performing systematic intradialytic exercise on the echocardiographic parameters of left ventricular diastolic function in hemodialysis patients?
Methodology
Study Design:
Study Population Description:
The target population is patients with chronic kidney disease who are currently receiving hemodialysis at the National Institute of Cardiology (prevalent hemodialysis patients).
Eligible Population:
Patients with chronic kidney disease, prevalent in hemodialysis, who are treated in the hemodialysis unit at the National Institute of Cardiology, with left ventricular diastolic function determined by echocardiographic measurement within a 6-month period from September 2023 to September 2024.
Once the inclusion criteria are met, a baseline transthoracic echocardiogram will be performed to determine and record the parameters that evaluate left ventricular diastolic function. If the patient presents any degree of diastolic dysfunction, the study will begin with a 16-week hemodialysis period without exercise. All echocardiograms will be performed before the first dialysis session of the week (Monday or Tuesday according to the patient's session schedule). At the end of the 16 weeks, a final transthoracic echocardiogram will be performed. The second phase of the study, which consists of hemodialysis with intradialytic exercise for 16 weeks, will then begin, and at the end of this period, another final transthoracic echocardiogram will be performed to determine diastolic function parameters. All echocardiograms will be performed before the first dialysis session of the week (Monday or Tuesday according to the patient's session schedule).
Evaluation of Intradialytic Exercise:
The prescription of intradialytic exercise will be based on the FITT-VP protocol, validated by the American College of Sports Medicine, which consists of the following points:
Based on this, a cardiopulmonary exercise test will be conducted by a sports medicine expert for all patients. Based on the results and according to Skinner's three-phase model, the prescribed workload will be determined by the first ventilatory threshold (VT1), which lies between training zones 1 and 2. Adjustments will be made according to the FITT-VP points as follows:
Frequency: Frequency: 3 times a week during the hemodialysis session (all patients)
Intensity: Low (no resistance), maintaining the VT1 watts throughout the session.
Time: Initially 45 minutes, increasing by 5 minutes each week, reaching 1 hour 30 minutes of exercise at the end of the study phase.
Type: Aerobic (stationary cycling).
Volume: Continuous pedaling during the hemodialysis session with work monitored in watts using power meters.
Progression: Progress will be recorded during the intradialytic exercise period.
Intradialytic exercise will be performed with a stationary bicycle model Urban fit PRO SH-612. Power meters (Favero Assioma UNO) will be inserted into the pedals and connected to a cycle computer (iGPSPORT BSC100S) to measure the workload in watts. The intradialytic exercise program will consist of pedaling during the hemodialysis session, with heart rate reserve monitored using the modified Karvonen method ((HRmax-HRrest)×(40-80%)+ HRrest) and Borg's Rating of Perceived Exertion Scale. A record will be kept for each session. Exercise prescription will be supervised by a sports medicine specialist, along with two medical interns trained in cardiopulmonary exercise testing, who will be responsible for registering and supervising the intradialytic exercise program.
Evaluation of Diastolic Function:
Diastolic function will be measured based on the international recommendations of the American and European Societies of Echocardiography published in 2016. The two-dimensional echocardiography study will be performed by two experienced cardiologists with current certification in echocardiography, using the Vivid Q GE ultrasound machine with a 3.5 MHz transducer. The following measurements will be taken:
Based on these parameters, measurements will be categorized into grades of diastolic dysfunction (1, 2, 3, or indeterminate) according to current guidelines for patients with either reduced or preserved LVEF as appropriate. Left atrial strain will be measured using tissue Doppler in an apical 4-chamber view with the speckle tracking method.
6-Minute Walk Test: The test will be conducted on the first day of the hemodialysis session (Monday or Tuesday) before the session, every 4 weeks. The test will be performed based on the guidelines of the American and European Thoracic Societies by two medical interns trained to administer the test.
General Practice Physical Activity Questionnaire (GPPAQ):
The GPPAQ questionnaire will be administered to each patient at the beginning and every 4 weeks thereafter, on the same day and before the 6-minute walk test. The GPPAQ is a self-administered questionnaire for adults consisting of 3 questions. The first question measures the type and amount of physical activity (PA) at work, the second asks about the time spent on different types of PA during the last week, and the third asks about the usual walking pace. The scoring system classifies patients into 4 levels of PA: inactive (sedentary work and no physical exercise or cycling), moderately inactive (sedentary work and <1 hour of physical exercise or cycling, or standing work without physical exercise or cycling), moderately active (sedentary work and 1-2.9 hours/week of physical exercise or cycling, or standing work and <1 hour/week of physical exercise or cycling, or physically active work without physical exercise or cycling), and active (sedentary work and ≥3 hours/week of physical exercise or cycling, or standing work and 1-2.9 hours/week of physical exercise or cycling, or physically active work and <1 hour of physical exercise or cycling, or work with vigorous PA).
Adverse Event Monitoring Adverse events will be monitored exclusively during the Intradialytic Exercise Phase (Intervention Period, 16 weeks). No exercise-related adverse events are expected during the Control Phase, as no exercise will be performed during that period. Arm for adverse event assessment: Intervention Period (Intradialytic Exercise). Adverse events during exercise, such as transient muscle fatigue or mild hemodynamic changes, will be recorded and classified. Any adverse event requiring session discontinuation will be documented and reported.
Ethics The study protocol was approved by the local Research and Ethics Committees under approval number PT 23-1378. This study was registered at ClinicalTrials.gov (NCT06584734). Written informed consent was obtained from all participants.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients were instructed to discontinue any unstructured exercise previously performed during their hemodiafiltration sessions for 16 weeks. Hemodiafiltration sessions continued unchanged according to the center's standard of care.
Other names: Control Phase, Rest, Control Period, Pre-Exercise
A 16 weeks of Intradialytic exercise program that is performed using cycle ergometers during the hemodiafiltration session. Exercise intensity is quantified in watts using power meters and is individualized according to each participant's performance on cardiopulmonary exercise testing (CPET).
Other names: Intervention period, Intradialytic Exercise
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Classification of left ventricular diastolic function into ordinal grades based on the 2016 ASE/EACVI guidelines. Classification is determined by integrating E/A ratio, average E/e' ratio, indexed left atrial volume (LAVi), and tricuspid regurgitation (TR) velocity. Grade 1 (mild, impaired relaxation) is the least severe; Grade 2 (moderate, pseudonormal filling) represents intermediate severity; Grade 3 (severe, restrictive filling) is the most severe.
Grading criteria: Grade 1 (mild - impaired relaxation): E/A < 0.8, average E/e' ≤ 14, LAVi ≤ 34 ml/m², TR velocity ≤ 2.8 m/s; fewer than 2 positive criteria. Grade 2 (moderate - pseudonormal filling): E/A 0.8-2.0, with ≥ 2 of the following positive: average E/e' > 14, LAVi > 34 ml/m², TR velocity > 2.8 m/s. Grade 3 (severe - restrictive filling): E/A > 2.0, or E/A 0.8-2.0 with all three criteria positive.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Peak longitudinal deformation of the left atrium during the reservoir phase measured by 2D speckle tracking echocardiography. Expressed as a percentage (%). Higher values indicate better left atrial reservoir function and, indirectly, less elevation in left ventricular filling pressures.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Assessment of myocardial deformation using 2D speckle tracking echocardiography. Values are expressed as a negative percentage (%); more negative values indicate better longitudinal contraction (e.g., -17.4% is better than -15.5%)
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Automated left ventricular ejection fraction (%), calculated using automated contour detection software applied to 2D echocardiographic images. Represents the proportion of blood ejected from the left ventricle with each heartbeat. Higher values indicate better left ventricular systolic function; values >= 52% are considered within normal range.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Tricuspid annular plane systolic excursion (TAPSE), measured in millimeters (mm) by M-mode echocardiography at the lateral tricuspid annulus. Reflects right ventricular longitudinal systolic function. Higher values indicate better right ventricular function; values >= 17 mm are considered within normal range.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention period)
Non-invasive estimate of left ventricular filling pressure calculated as the ratio of early diastolic mitral inflow velocity (E wave, pulsed-wave Doppler) to the average of septal and lateral mitral annular early diastolic velocities (e', tissue Doppler imaging). Higher values indicate elevated filling pressures.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention period)
Ratio of early diastolic (E wave) to late diastolic (A wave) mitral inflow velocities measured by pulsed-wave Doppler echocardiography with the sample volume placed at the mitral valve leaflet tips, apical four-chamber view. Reflects left ventricular relaxation and filling patterns.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention period)
Left atrial volume indexed to body surface area (ml/m^2) measured by the biplane Simpson method using apical four-chamber and two-chamber views. Reflects left atrial structural remodeling as a marker of chronic elevation in left ventricular filling pressures. Lower values indicate less atrial remodeling and are associated with better diastolic function; values <= 34 ml/m2 are within the normal range per ASE 2016 guidelines.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention period)
Peak tricuspid regurgitation velocity (cm/s) assessed by continuous-wave Doppler echocardiography, used to estimate right ventricular systolic pressure and pulmonary artery pressure per the 2016 ASE/EACVI diastolic function guidelines. Lower values are associated with lower estimated pulmonary pressures and less severe diastolic dysfunction; values <= 2.8 m/s are within the normal range.
Time frame: 16 weeks (end of control period), and 32 weeks (end of intervention)
General Practice Physical Activity Questionnaire. Self-administered questionnaire for adults consisting of 3 questions assessing type and amount of physical activity at work, during leisure time, and usual walking pace. Classifies patients into 4 levels: Inactive, Moderately Inactive, Moderately Active, and Active. Higher activity levels represent better physical activity status; Active is the most favorable and Inactive is the least favorable category.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Total distance in meters (m) that a patient can quickly walk on a flat, hard surface in a period of 6 minutes based on the guidelines of the American and European Thoracic Societies by two medical interns, who are trained to perform the test. It assesses functional capacity and response to the exercise intervention. Greater distances indicate better functional exercise capacity.
Time frame: 16 weeks (end of control period), and 32 weeks (end of intervention)
Peak workload (maximal power output) is defined as the highest power output (in watts) achieved during a symptom-limited incremental CPET on a cycle ergometer, corresponding to the last fully completed workload stage or the highest workload maintained for ≥30 seconds. Higher values indicate greater maximal aerobic exercise capacity.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Power output (watts) achieved during a cardiopulmonary exercise test (CPET) at the point of the first ventilatory threshold (VT1) -- the exercise intensity above which ventilation begins to increase disproportionately to oxygen consumption. Higher values indicate greater aerobic exercise capacity and improved cardiovascular fitness.
Time frame: 16 weeks (end of control period) and 32 weeks (end of intervention)
Maximum rate of oxygen consumption (VO2 max) measured during incremental exercise on a cycle ergometer, expressed in milliliters per kilogram per minute (ml/kg/min). Reflects overall cardiorespiratory fitness and aerobic capacity. Higher values indicate better cardiovascular fitness; values < 17.5 ml/kg/min in dialysis patients are associated with increased cardiovascular risk.
Instituto Nacional de Cardiologia Ignacio Chavez
Other
Acronym: EXE-HDF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01021839
Arteriovenous Fistula, Arteriovenous Malformations
Boston, Massachusetts, United States
View Trial DetailsNCT07160452
Anemia, Chronic Disease
View Trial DetailsNCT03825770
Chronic Disease, Disease Attributes
Calgary, Alberta, Canada
View Trial DetailsNCT02461953
Hemoperfusion, Quality of Life
Beijing, Beijing Municipality, China
View Trial Details